Create Free Account

By creating account you will get access to hot stocks & personalised emails

Atara Biotherapeutics Inc

Healthcare US ATRA

10.1USD
0.29(2.96%)

Last update at 2024-12-19T18:43:00Z

Day Range

9.1310.35
LowHigh

52 Week Range

6.5039.50
LowHigh

Fundamentals

  • Previous Close 9.81
  • Market Cap73.84M
  • Volume82077
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-162.12499M
  • Revenue TTM62.39M
  • Revenue Per Share TTM12.26
  • Gross Profit TTM 63.57M
  • Diluted EPS TTM-25.32

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -276.11100M -228.29000M -340.09500M -306.60500M -290.96400M
Minority interest - - - - -
Net income -276.12600M -228.30200M -340.14100M -306.62000M -290.97600M
Selling general administrative 50.91M 71.55M 78.80M 64.40M 79.58M
Selling and marketing expenses 1.11M - - - -
Gross profit -0.31300M 49.01M 20.34M -9.86700M -8.10500M
Reconciled depreciation 4.88M 5.65M 9.35M 8.33M 7.07M
Ebit -269.27600M -280.51300M -340.46200M -309.05200M -295.68100M
Ebitda -264.44700M -330.75000M -331.11700M -300.72000M -288.61100M
Depreciation and amortization 4.83M -50.23700M 9.35M 8.33M 7.07M
Non operating income net other - 52.22M 0.37M 2.45M 4.72M
Operating income -269.27600M -280.51300M -340.46200M -309.05200M -295.68100M
Other operating expenses 277.85M 344.09M 360.80M 309.05M 295.68M
Interest expense 5.29M 1.99M 9.71M 10.78M 11.79M
Tax provision 0.00600M 0.01M 0.05M 0.01M 0.01M
Interest income 4.80M 1.99M 0.37M 2.45M 4.72M
Net interest income 0.94M 1.99M 0.37M 2.45M 4.72M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01M 0.01M 0.05M 0.01M 0.01M
Total revenue 8.57M 63.57M 20.34M 3.55M 0.00000M
Total operating expenses 268.96M 344.09M 360.80M 309.05M 295.68M
Cost of revenue 8.89M 14.57M 11.38M 9.87M 8.11M
Total other income expense net -6.83500M 52.22M 0.37M 2.45M 4.72M
Discontinued operations - - - - -
Net income from continuing ops -290.24800M -228.30200M -340.14100M -306.62000M -290.97600M
Net income applicable to common shares - -228.30200M -340.14100M -306.62000M -290.97600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 165.50M 376.42M 468.13M 588.12M 342.94M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.18M 10.31M 12.57M 21.36M 13.88M
Total liab 264.74M 249.78M 188.51M 125.78M 52.16M
Total stockholder equity -99.23100M 126.64M 279.61M 462.34M 290.78M
Deferred long term liab - - - - -
Other current liab 48.53M 50.41M 44.91M 40.34M 5.73M
Common stock 0.01M 0.01000M 0.00900M 0.00800M 0.00600M
Capital stock 0.01M 0.01000M 0.00900M 0.00800M 0.00600M
Retained earnings -1969.15000M -1693.02400M -1464.72200M -1124.58100M -817.96100M
Other liab - 109.16M 57.21M 29.69M 1.04M
Good will - - - - -
Other assets 0.00000M 7.02M 3.57M 14.33M 1.77M
Cash 25.99M 92.94M 106.08M 200.40M 74.32M
Cash and equivalents - - - - -
Total current liabilities 142.23M 78.92M 105.79M 82.90M 36.74M
Current deferred revenue 77.83M 8.00M 40.76M 33.45M 21.47M
Net debt 31.89M -21.23800M -80.56600M -187.36300M -60.18100M
Short term debt 12.18M 13.64M 2.75M 1.99M 1.58M
Short long term debt - - - - -
Short long term debt total 57.87M 71.70M 25.52M 13.04M 14.14M
Other stockholder equity 1870.11M 1821.72M 1744.69M 1586.62M 1108.52M
Property plant equipment - 6.30M 79.94M 50.52M 54.18M
Total current assets 101.87M 295.08M 384.62M 523.27M 272.99M
Long term investments - - - - -
Net tangible assets - 126.64M 279.61M 462.34M 290.78M
Short term investments 25.88M 149.88M 264.98M 300.25M 184.79M
Net receivables 34.11M 40.22M 0.99M 1.25M -
Long term debt - - - - -
Inventory 9.71M 1.59M - - -
Accounts payable 3.68M 6.87M 17.37M 7.12M 7.96M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.20400M -2.06700M -0.36800M 0.30M 0.22M
Additional paid in capital - - - - -
Common stock total equity - 0.01000M 0.00900M 0.00800M 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - -1693.02400M -1464.72200M -1124.58100M -817.96100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.84M 7.02M 3.57M 2.03M 1.77M
Deferred long term asset charges - - - - -
Non current assets total 63.63M 81.34M 83.51M 64.85M 69.95M
Capital lease obligations 57.87M 71.70M 25.52M 15.03M 15.72M
Long term debt total - - - - 0.24M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 165.14M 112.38M 32.84M -116.21500M 66.03M
Change to liabilities - -25.74900M 44.28M 66.78M 7.89M
Total cashflows from investing activities - 202.96M 22.26M -120.72800M 60.46M
Net borrowings - 30.09M -0.25400M -0.38900M -0.48600M
Total cash from financing activities 2.01M 53.08M 103.94M 427.57M 188.79M
Change to operating activities - 0.03M 8.04M 4.50M -8.36100M
Net income -276.12600M -228.30200M -340.14100M -306.62000M -290.97600M
Change in cash -67.10100M -14.39000M -94.32000M 126.09M 13.62M
Begin period cash flow 93.09M 107.48M 201.80M 75.71M 62.09M
End period cash flow 25.99M 93.09M 107.48M 201.80M 75.71M
Total cash from operating activities -192.97700M -270.43000M -220.52200M -180.75900M -235.62600M
Issuance of capital stock 32.57M 52.50M 98.70M 422.97M 188.62M
Depreciation 4.83M 5.65M 9.35M 8.33M 7.07M
Other cashflows from investing activities - 94.77M - - 0.16M
Dividends paid - 0.62M 1.24M 1.52M 6.70M
Change to inventory -8.12000M -1.58600M 3.34M -1.25200M -1.58600M
Change to account receivables 6.11M -39.23500M 0.26M -1.25000M -1.25000M
Sale purchase of stock -0.09400M -0.62300M -1.24400M -1.52100M -6.69500M
Other cashflows from financing activities -0.10700M 2.35M 7.99M 8.04M 14.04M
Change to netincome - 3.60M 57.60M 51.48M 52.72M
Capital expenditures 1.22M 4.19M 10.58M 4.51M 5.73M
Change receivables - -39.23500M 0.26M -1.25000M -
Cash flows other operating - 14.16M 4.18M -0.38600M -11.07300M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -14.39000M -94.32000M 126.09M 13.62M
Change in working capital 15.34M -61.46800M 52.58M 63.69M -4.14800M
Stock based compensation 45.39M 53.84M 53.87M 51.35M 51.70M
Other non cash items 12.46M -40.15100M 2.04M 1.53M 1.03M
Free cash flow -194.20000M -274.62300M -231.10200M -185.27200M -241.35900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATRA
Atara Biotherapeutics Inc		 0.29 2.96% 10.10 - - 1.18 1.97 0.58 -0.3471
NVO
Novo Nordisk A/S		 -2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics Inc

2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320

Key Executives

Name Title Year Born
Dr. Pascal Touchon D.V.M. Pres, CEO & Director 1963
Mr. Utpal Koppikar M.B.A. Exec. VP & CFO 1971
Mr. K. Amar Murugan Sr. VP & Gen. Counsel 1975
Dr. Jakob Dupont M.D. Exec. VP and Global Head of R&D 1965
Ms. Charlene Banard Chief Technical Officer 1963
Dr. Anhco Nguyen Chief Scientific Officer 1973
Eric Hyllengren VP of Investor Relations & Fin. NA
Kerry Beth Daly Head of Corp. Communications NA
Ms. Amie Krause Chief People Officer NA
Mr. Joseph Newell Exec. VP 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.